Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “IMIPRAMINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,711 records · Page 95Linked to original sources

High- and low-affinity [3H]imipramine binding sites on human platelets: separate determination and involvement of sulphur-containing bonds.

We have confirmed the presence of two different classes of [3H]imipramine ([3H]IMI) binding sites on human platelets: high-affinity (Kd = 0.52 nM, Bmax = 1670 fmol/mg protein) and low-affinity (Kd = 101 nM, Bmax = 8,000 fmol/mg protein) binding sites. The high-affinity component of [3H]IMI binding can also be obtained separately as the difference between specific [3H]IMI binding in Na-containing and Li-containing incubation buffer. The low-affinity component can be obtained as the difference between [3H]IMI binding in 50 mM Tris-HCl, 5 mM KCl, 120 mM LiCl, (pH 7.5) in the absence and presence of 0.1 mM IMI. The chemical modification of SH groups was performed with Ellman's reagent (10 mM, 40 min at 23 degrees C). The high-affinity component of the binding was totally inhibited while the low-affinity component only decreased by 39%. No decrease in [3H]IMI specific binding was observed when the modification of SH groups was carried out in the presence of 1 microM IMI. The inhibition of high- and low-affinity [3H]IMI binding was reversible since it was completely restored by incubation of modified membranes with 1,4-dithioerythritol (DTE). The reduction of SS groups by DTE (10 mM, 1 h at 23 degrees C) in the intact membrane preparation produced an increase in total number of binding sites of the high-affinity component of [3H]IMI binding by 50%.

Adult↗

Changes in urinary catecholamines and their metabolites in depressed patients treated with amitriptyline or imipramine.

The effects of treatment with amitriptyline (AMI) or imipramine (IMI) on changes in catecholamines and their metabolites in urine were studied in 95 unipolar and bipolar depressed patients. For the entire group, not separated by drug, substantial reduction in concentrations of all metabolites, but not catecholamines, occurred. Although catecholamine and metabolite change was similar for most substances assayed, there were some specific drug and diagnostic group differences. Vanillylmandelic acid (VMA) reduction was limited to bipolar patients; metanephrine (M) reduction to unipolar patients. Greater M and 3-methoxy-4-hydroxyphenylglycol (MHPG) reduction were associated with response in unipolar, but not bipolar patients. In bipolar, but not unipolar patients, norepinephrine (NE) rose in responders in contrast to reductions among nonresponding bipolar patients. The results suggest that effectiveness of blockade of reuptake of norepinephrine may be relatively more important for recovery in bipolar than in unipolar patients. Study of a battery of amine substances may contribute more information to our understanding of antidepressant drug effects on aminergic systems than analyses of MHPG alone.

Adult↗

Platelet imipramine binding in patients with panic disorder and major familial depression.

Platelet 3H-imipramine binding was investigated in 15 normal subjects, 17 patients with major depressive disorder and 43 patients with panic disorder, to further study the relationship between depressive and anxiety disorders. Whereas patients with major depression had a significantly lower mean Bmax value than healthy volunteers, mean Bmax values in patients with panic disorder did not differ significantly from normal controls. Furthermore, apparently normal Bmax values were observed even in those panic disorder patients who had concurrent major depression or a past history of depression. Thus, despite previous findings of an overlap between panic and depressive disorders, the present results suggest that the two syndromes may have distinct neurochemical substrates.

Adult↗

Influence of age, sex and diurnal variability on imipramine receptor binding and serotonin uptake in platelets of normal subjects.

Imipramine (IMI) binding and serotonin (5-HT) uptake were determined in platelets of 98 healthy volunteers; and their association with age, sex and circadian rhythm were evaluated. A large interindividual variability was found for both IMI and 5-HT parameters. There was a negative correlation of IMI affinity constant (Kd) and binding (Bmax) with age, but no such correlation of 5-HT affinity constant (Km) or uptake (Vmax). Significant age-related diurnal variability was found for 5-HT Km in the whole group as well as for IMI Kd in males, but not in females. There was no significant correlation between 5-HT Vmax and IMI Bmax. Our results underscore a cautious approach to the interpretation of platelet serotonergic studies. In light of the multiple variables influencing the results, the usefulness of IMI or 5-HT as clinical markers should be re-evaluated.

Adult↗

Platelet [3H]imipramine binding in migraine and tension headache in relation to depression.

Platelet [3H]imipramine binding was measured in 40 migrainous (7 classical and 33 common) and 17 tension headache patients and in 28 normal controls. A significant reduction in Bmax was found in migraine compared with controls (p less than 0.05) but not in tension headache. In migraine, there was no significant relationship between Bmax and depression or anxiety score on the self-rating Hospital Anxiety and Depression (HAD) Scale, suggesting that the reduction in Bmax is a concomitant of migraine itself rather than a manifestation of associated depression. Preliminary evaluation using the Schedule of Affective Disorders and Schizophrenia-Lifetime Version (SADS-L) tended to confirm this conclusion.

Adult↗

Effects of imipramine on tyrosine and tryptophan are mediated by beta-adrenoceptor stimulation.

Imipramine (IMI; 20 mg/kg) in rats decreased the plasma tyrosine concentration by 21% (90 min), whereas norepinephrine (NE; 1.25 mg/kg) raised it by 72% (40 min). Since NE raised plasma tyrosine by stimulating alpha-adrenoceptors, as shown by phenoxybenzamine (PB) completely abolishing this increase, an experiment was done to find out whether IMI lowered plasma tyrosine by blocking alpha-adrenoceptors. In contrast to PB, IMI pretreatment failed to alter the NE-induced elevation in plasma tyrosine, suggesting that at this dose IMI is not an effective alpha-adrenergic antagonist in vivo. Thus, IMI would not appear to reduce plasma tyrosine by blocking alpha-adrenoceptors. In a separate experiment, propranolol blocked the ability of IMI to lower plasma tyrosine. Propranolol also prevented a 17% elevation in brain tryptophan levels induced by IMI but did not alter the 29% decrease in plasma tryptophan. PB by itself decreased plasma tyrosine, but this decrease was not greater by additionally treating with IMI. Salbutamol (10 mg/kg), a beta 2 agonist, lowered plasma tyrosine to 76% and raised brain tryptophan to 143% of control. These results suggest that IMI decreases tyrosine concentrations in plasma and raises tryptophan in brain by stimulating beta-adrenoceptors.

Animals↗

Down-regulation of 3H-imipramine binding sites in rat cerebral cortex after prenatal exposure to antidepressants.

Several antidepressant drugs were given to pregnant rats in the last 15 days of gestation and 3H-imipramine binding (3H-IMI) was subsequently measured in the cerebral cortex of the offspring. The selective serotonin (5-HT) uptake blockers chlorimipramine and fluoxetine as well as the selective monoamine oxidase (MAO) inhibitors clorgyline and deprenyl induced, after prenatal exposure, a down-regulation of 3H-IMI binding sites at postnatal day 25. The density of these binding sites was still reduced at postnatal day 90 in rats exposed in utero to the MAO inhibitors. The antidepressants desipramine and nomifensine were ineffective in this respect. After chronic treatment of adult animals, only chlorimipramine was able to down-regulate the 3H-IMI binding sites. Consequently, prenatal exposure of rats to different antidepressant drugs affecting predominantly the 5-HT systems induces more marked and long-lasting effects on cortical 3H-IMI binding sites. The results suggest that the developing brain is more susceptible to the actions of antidepressants.

Analysis of Variance↗

Imipramine-fentanyl antinociception in a rabbit tooth pulp model.

Antinociception of imipramine (I) and its effect in combination with fentanyl (F) was evaluated in rabbits using electrically-induced lick chew responses via tooth pulp stimulation as the model of nociception. Acute i.v. injections of I elicited a graded dose response comparable to i.v. morphine (M) with I ED 50 = 4.35 mg/kg (2.31-8.14, 95% CL) and M ED 50 = 1.81 mg/kg (1.11-3.90), with no differences in the slopes between the two curves. The lethal dose of I was 10 mg/kg. An i.v. dose of I twice the ED 50 elicited an antinociceptive effect of more than 50% maximum possible effect (MPE) for 90 minutes with peak effect of 82% MPE occurring at 15 minutes. These effects of I were not reversed by a morphine-reversal dose of naloxone (0.1 mg/kg i.v.) but were reversed with a ten fold dose of naloxone. F ED 50 values (mcg/kg) were lowered from 11.35 to 2.70, 0.74 and 0.33 with increasing pretreatment doses of I (1.0, 2.1 and 3.2 mg/kg). These magnitudes of potency increases of F were 4.2, 15.3 and 34.4 fold respectively. A single i.v. ED 50 dose of I extended the time to 50% MPE of an ED 90 dose of F from 26 minutes to 77 minutes; of a 2 X ED 50 dose of F from 17 minutes to 28 minutes. Data points for three different combinations of I and F fell significantly within the synergistic field of an ED 50 isobologram and a polynomial equation described the curve best fitting the data points. F alone (i.v. ED 50 dose) increased the PaCO2 values to 74% above controls and three different combinations with I showed no increases in PaCO2 values above controls. I alone did not significantly cause any change in PaCO2 values from controls.

Analgesics↗

Chronic variable stress facilitates tumoral growth: reversal by imipramine administration.

The present study was conducted to examine whether a chronic variable stress procedure (CVS)--an animal model of depression--facilitates tumor growth, and whether this effect can be modified by concurrent administration of the antidepressant imipramine (IMI). Unstressed rats, with or without previous administration of the immunosuppressive agent cyclosporine (CS), were inoculated with 5 x 10(6) cells of a sarcoma. Another group of rats was inoculated with tumoral cells and later exposed to the CVS procedure with or without concurrent administration of IMI (10 mg/kg, i.p.). An additional group of animals was treated with CS and later given daily injections of IMI (10 mg/kg, i.p.) without stress manipulation. A lack of tumoral development was observed in unstressed animals without previous injections of CS, whereas, prior injections of this immunosuppressive agent increased tumoral growth in unstressed animals. Exposure to the CVS procedure facilitated tumoral growth even in animals without CS injections. This effect was clearly attenuated when chronically stressed rats were concurrently given IMI. These findings support the notion that the development of a tumoral process is facilitated when a state of experimental depression is induced and that the reversal of such a state by antidepressant treatment results in the inhibition of tumor development.

Animals↗

Rapid desensitization of central beta-adrenoceptors in rat after subacute treatment with imipramine and calcium entry blockers.

The subcutaneous (s.c.) administration of isoprenaline to rats produced a dose-dependent increase in water drinking which was effectively antagonized by propranolol. This dipsogenic response was significantly inhibited after the intraperitoneal (i.p.) administration of imipramine (15 mg/kg/day), together with either of the following calcium entry blockers, for four days: diltiazem (15 mg/kg/day), verapamil (10 mg/kg/day), nifedipine (10 mg/kg/day) or nicardipine (15 mg/kg/day). Simultaneous injection of the inhibitor of the synthesis of serotonin, p-chlorophenylalanine (200 mg/kg/day, i.p.), did not affect this attenuation of the isoprenaline-induced response. Similarly, the selective 5-HT2 receptor agonist, 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) or the 5-HT2 receptor antagonist, ketanserin, had no significant effect on the attenuation of isoprenaline-induced drinking behaviour. The inhibition of isoprenaline-induced drinking, was, however, effectively attenuated after treatment of the animals with 6-hydroxydopamine (2.5 micrograms) or clonidine (30 micrograms), injected intracerebroventricularly (i.c.v.). These results indicate that the calcium entry blockers accelerate the desensitization of central beta-adrenoceptors possibly by an action on central adrenoceptors of the rat.

1-Propanol↗

Imipramine for aspermia after lymphadenectomy.

During radical retroperitoneal lymphadenectomy the hypogastric sympathetic plexus is necessarily partially sacrificed, with resultant failure of part of the ejaculatory mechanism and aspermia. We have observed this condition to be reversible with imipramine.

Adult↗

Incentive contrast undiminished by extended testing, imipramine, or chlordiazepoxide.

In three experiments rats were given alternating 1-minute access periods to two tubes containing sucrose solutions. When the tubes contained disparate concentrations (32% versus 4%), lick-rate was higher for the 32% solution than it was when both tubes contained 32% (a positive contrast effect) and less for 4% than when both tubes contained 4% (a negative contrast effect). Similar, but generally less pronounced, contrast effects were obtained in latency to initiate drinking. These contrast effects showed no sign of diminution with repeated exposure (32 days of repeated shifts in Experiments 1 and 3); they were not greatly influenced by injections of imipramine (Experiment 2) or chlordiazepoxide (Experiment 3), nor by deprivation conditions (Experiment 3), nor by deprivation conditions (Experiment 3). The results supported an explanation of simultaneous contrast in terms of sensory-perceptual processes rather than in terms of generalization decrement or emotional responses.

Animals↗

Effect of imipramine on serotonin turnover in the lateral hypothalamus.

One hour following an infusion of 3H-5-hydroxytryptamine, animals were injected with either 15 mg/kg imipramine hydrochloride or 0.9% NaCl and then the lateral hypothalamus was perfused for 40 min. Samples of perfusate were analyzed by thin layer chromatography for estimation of 3H-labelled 5-hydroxytryptamine and metabolites. The results indicate that impramine hydrochloride 15 mg/kg decreases serotonin release and turnover in the lateral hypothalamus.

Animals↗

A further parametric study of imipramine in an animal model of depression.

We have proposed that chronic stress may produce motivational, behavioral, and neuroendocrine symptoms in rats resembling endogenous depression in humans. The chronic stress model has proved responsive to chronic treatment by antidepressant drugs. Two issues concerning this effect remain unresolved, these being; the requirement of drug chronicity, and treatment outcome to different drug doses. The present experiment examined both issues in a factorial design in which vehicle and two doses of the tricyclic antidepressant imipramine were varied across 2 treatment periods; acute (1 hr) and chronic (3 weeks). Both factors were found to significantly interact with treatment outcome, suggesting that chronic treatment is necessary for recovery and that this outcome is dependent upon drug level.

Animals↗

Anti-muricide mechanisms of chlorpromazine and imipramine in OB rats: adrenoceptors and hypothalamic functions.

Chlorpromazine (CPZ) microinjected into the posterior part of the lateral hypothalamus (p-LH) and the lateral preoptic area (1-POA) of OB rats shows anti-muricide and cataleptogenic effects as well as a drowsy pattern in cortical EEG, while imipramine (IMP) injected into p-LH shows anti-muricide and cataleptogenic effects without change of cortical EEG. The present study examined the effects of drugs injected into p-LH and 1-POA on muricide, catalepsy and cortical and limbic EEG. CPZ (20, 50 micrograms) suppressed muricide and induced catalepsy and an EEG drowsy pattern in the two regions. The effects of CPZ in p-LH were similar to those of propranolol (PRO). In 1-POA, the anti-muricide effect of CPZ was similar to that of phenoxybenzamine, whereas the cataleptogenic and EEG effects were similar to those of PRO. IMP (10, 20 micrograms) in p-LH showed anti-muricide and cataleptogenic effects and induced a slight drowsy pattern in limbic EEG. The effects were similar to those of atropine. Lidocaine did not show any effects in the two regions. The cataleptogenic effects of CPZ and IMP did not appear related with the anti-muricide effects. The results suggest that the anti-muricide effect of CPZ in the hypothalamus depends on its adrenoceptor blockage, while that of IMP relates to its anticholinergic effect. In addition, beta-receptors in the hypothalamus appear related to the arousal system and dopaminergic functions.

Aggression↗

Different effects of short- and long-term treatment with imipramine on the apomorphine- and food-induced place preference conditioning in rats.

The effect of imipramine (IMI) on the rewarding properties of pharmacological and natural reinforcers was studied with a place preference paradigm. The pairing of distinctive environmental stimuli with either injection of different doses of apomorphine (APO) or presentation of food to hungry rats resulted in a conditioned preference for those stimuli. The development of APO- and food-induced place preference was prevented by short-term administration of IMI. In contrast, long-term pretreatment with IMI significantly potentiated the APO- and food-induced conditioned effect. In separate experiments aversive properties of IMI by itself were also found, as the conditioned avoidance response to the environmental stimuli paired with administration of single doses of IMI was demonstrated. The results indicate an enhancing effect of the long-term IMI administration on the dopamine-mediated reward functions and the rewarding value of natural reinforcers.

Animals↗

Shuttle-box deficits induced by chronic variable stress: reversal by imipramine administration.

Escape performance in a shuttle-box task was evaluated in rats chronically exposed to a series of unpredictable stressors either during 14 or 7 consecutive days. Failure in escape responses was observed when animals were subjected to both regimes of variable aversive situations. The association between chronic exposure to unpredictable stressors with imipramine resulted in a significant reversal of escape deficits. Furthermore, animals submitted to repeated immobilization sessions during 7 days presented similar escape response to control rats. A possible involvement of beta-adrenergic sites on this behavioral response is discussed.

Animals↗

Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats.

Dizocilpine coadministered with imipramine (IMI) through an SC-implanted osmotic minipump completely prevents the occurrence of behavioral supersensitivity to quinpirole, as well as the decrease of dopamine D1 and beta-adrenergic receptor function. The present report shows that, in the same experimental conditions, dizocilpine completely antagonized the capacity of IMI to prevent the development of the learned helplessness behavior in rats. Thus suggesting that the blockade of NMDA receptors also antagonizes the antidepressant effect of IMI. Interestingly, rats acutely treated with dizocilpine 30 min before the inescapable shock session behaved similarly to naive animals during the escape test session.

Animals↗